目的 探讨依达拉奉联合卡马西平治疗脑梗死后继发性癫痫的临床疗效。方法 选取2015年2月—2016年10月在海南省第二人民医院接受治疗的脑梗死后继发性癫痫患者40例，根据治疗方法的差别分为对照组（20例）和治疗组（20例）。对照组患者口服卡马西平片，0.2 g/次，2次/d。治疗组在对照组的基础上静脉滴注依达拉奉注射液，30 mg加入生理盐水100 mL中，2次/d。两组患者均连续治疗4周。比较两组患者治疗前后临床疗效、痫样放电、累及导联数和癫痫发作频率变化。结果 治疗后，对照组和治疗组的总有效率分别为70.00%、85.71%，两组总有效率比较差异具有统计学意义（P< 0.05）。治疗后，两组患者痫样放电、累及导联数和癫痫发作频率均较治疗前显著降低，同组治疗前后比较差异具有统计学意义（P< 0.05）；且治疗组上述观察指标比对照组更低，两组比较差异具有统计学意义（P< 0.05）。结论 依达拉奉联合卡马西平治疗脑梗死后继发性癫痫的临床效果显著，可有效控制癫痫发作及降低血清细胞因子水平，具有一定的临床推广应用价值。

Objective To investigate the clinical efficacy of edaravone combined with carbamazepine in treatment of secondary epilepsy after cerebral infarction. Methods Patients (40 cases) with secondary epilepsy after cerebral infarction in the Second People's Hospital of Hainan Province from February 2015 to October 2016 were divided into control (20 cases) and treatment (20 cases) groups based on different treatments. Patients in the control group were po administered with Carbamazepine Tablets, 0.2 g/time, twice daily. Patients in the treatment group were iv administered with Edaravone Injection on the basis of the control group, 30 mg added into normal saline 100 mL, twice daily. Patients in two groups were treated for 4 weeks. After treatment, the clinical efficacy, epileptiform discharges, involved lead number, and seizure frequency in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the control and treatment groups were 70.00% and 85.71%, respectively, and there was difference between two groups (P < 0.05). After treatment, the epileptiform discharges, involved lead number and seizure frequency in two groups significantly decreased, and the difference was statistically significant in the same group (P < 0.05). And these observation indicators in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P < 0.05). Conclusion Edaravone combined with carbamazepine can effectively control the seizure and reduce serum cytokine levels in treatment of secondary epilepsy after cerebral infarction, which has a certain clinical application value.